Related Experiment Video
Updated: Mar 26, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11.1K
[Metastatic bronchial carcinoid tumors].
K Bouledrak1, T Walter2, P J Souquet1
1Service de pneumologie aiguë spécialisée et cancérologie thoracique, centre hospitalier Lyon-Sud, hospices civils de Lyon, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Université Lyon 1, 69100 Villeurbanne, France.
Revue De Pneumologie Clinique
|February 3, 2016
Summary
Bronchial carcinoids are rare lung tumors. Metastatic forms require a dual treatment approach targeting both tumor growth and carcinoid syndrome symptoms.
Area of Science:
- Oncology
- Pulmonary Medicine
- Endocrinology
Background:
- Bronchial carcinoids are uncommon lung neoplasms, accounting for 1-2% of all lung tumors.
- Surgery is the primary curative treatment for early-stage disease.
- Metastatic dissemination is unusual, and management strategies for advanced disease are not standardized.
Purpose of the Study:
- To review and discuss the management of metastatic bronchial carcinoids.
- To highlight the unique therapeutic challenges and approaches for this rare condition.
Main Methods:
- Review of existing literature and treatment strategies for neuroendocrine tumors.
- Application of established treatment protocols from gastrointestinal and pancreatic neuroendocrine tumors.
- Consideration of the specific characteristics of bronchial carcinoids.
Main Results:
- Metastatic bronchial carcinoids present unique challenges due to their rarity.
- Treatment strategies often adapt approaches used for gastrointestinal and pancreatic neuroendocrine tumors.
- A dual therapeutic approach is essential for managing metastatic disease.
Conclusions:
- Metastatic bronchial carcinoids necessitate a dual therapeutic strategy.
- This approach combines anti-tumoral treatments with anti-secretory therapies for carcinoid syndrome.
- Further research is needed to standardize management protocols for metastatic bronchial carcinoids.
